Delving into the Latest Updates on Hubei Minkang Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

GR x H1 receptor x M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor	1

主要目的：以持证商为Novartis Europharm Limited的磷酸芦可替尼片（20mg）为参比制剂，以湖北民康制药有限公司研制的磷酸芦可替尼片（20mg）为受试制剂，评价两种制剂在中国健康试验参与者中空腹状态下的生物等效性。次要目的：评价受试制剂和参比制剂在中国健康试验参与者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of ruxolitinib phosphate tablets (20 mg) manufactured by Novartis Europharm Limited as the reference formulation and ruxolitinib phosphate tablets (20 mg) manufactured by Hubei Minkang Pharmaceutical Co., Ltd. as the test formulation in healthy participants in a Chinese trial under fasting conditions. Secondary objective: To evaluate the safety of the test and reference formulations in healthy participants in a Chinese trial.

Start Date03 Jun 2026

Sponsor / Collaborator

Hubei Minkang Pharmaceutical Co. Ltd.

CTR20260396

/ CompletedNot Applicable

巴瑞替尼片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验

[Translation] Human bioequivalence clinical trials of baricitinib tablets in healthy Chinese populations under fasting and postprandial conditions with single-dose administration

主要目的：以持证商为Eli Lilly Nederland B.V.的巴瑞替尼片（商品名：Olumiant®，规格：4mg）为参比制剂，以湖北民康制药有限公司研发的巴瑞替尼片（规格：4mg）为受试制剂，评价两种制剂在中国健康参与者中空腹和餐后状态下的生物等效性。次要目的：观察受试制剂和参比制剂在中国健康参与者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of baricitinib tablets (trade name: Olumiant®, strength: 4 mg) manufactured by Eli Lilly Nederland B.V. as the reference formulation and baricitinib tablets (strength: 4 mg) developed by Hubei Minkang Pharmaceutical Co., Ltd. as the test formulation in healthy Chinese participants under fasting and postprandial conditions. Secondary objective: To observe the safety of the test and reference formulations in healthy Chinese participants.

Start Date05 Mar 2026

Sponsor / Collaborator

Hubei Minkang Pharmaceutical Co. Ltd.

100 Clinical Results associated with Hubei Minkang Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Hubei Minkang Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Hubei Minkang Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Hubei Minkang Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Promethazine Hydrochloride/Sulfogaiacol/Ammonium Chloride ( GR x H1 receptor x M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor )	Bronchiectasis More	Approved